Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12055886 | 0.97 | ALDH1A1 (0.50) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL13895095 | 0.88 | ALDH1A1 (0.44) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL20465002 | 0.85 | TDP1 (0.48) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL690245 | 0.85 | ALDH1A1 (0.45) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL8967500 | 0.84 | HRH3 (0.44) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL28726647 | 0.84 | ALDH1A1 (0.46) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL6678765 | 0.83 | HRH3 (0.62) | HRH3ALDH1A1TSHRMAPTPOLB | |
| SCHEMBL8966776 | 0.82 | HRH3 (0.43) | HRH3ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL8495022 | 0.82 | HRH3 (0.52) | HRH3ALDH1A1TSHRALOX15MAPT | |
| SCHEMBL19841298 | 0.81 | ALDH1A1 (0.42) | HRH3ALDH1A1TSHRALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
| US-6770661-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2004-08-03 | — | — | US | disclosed |
| EP-1432424-A1 | HETEROCYCLIC SUBSTITUTED 2- (4-PHENOXY) PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEURONAL DAMAGE AND NEURODEGENERATIVE CONDITIONS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | disclosed |
| US-20030073724-A1 | Aryl substituted pyridines and their use | PURDUE PHARMA L.P. | 2003-04-17 | — | — | US | disclosed |
| WO-2003022285-A1 | HETEROCYCLIC SUBSTITUTED 2- (4-PHENOXY) PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEURONAL DAMAGE AND NEURODEGENERATIVE CONDITIONS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | APOB, LDLR, CETP | HRH3 218/4885ALDH1A1 1853/4885TSHR 1243/4885 |
| US-20030073724-A1 | Aryl substituted pyridines and their use | CACNA1S, SCN1A, SMN1; SMN2 | HRH3 1689/4885ALDH1A1 32/4885TSHR 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.